EDN1 and congenital diaphragmatic hernia: In this study the increasing rate of bosentan use from the ET-1 low to intermediate and high groups again supports a correlation between ET-1 levels and PH severity and support the promising role of the ET-1 pathway as a therapeutic target in CDH.